相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for ΔNp63α
Simona Citro et al.
BRITISH JOURNAL OF CANCER (2019)
Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer
Ayesha Murtuza et al.
CANCER RESEARCH (2019)
Combined Inhibition of HDAC and EGFR Reduces Viability and Proliferation and Enhances STAT3 mRNA Expression in Glioblastoma Cells
Marienela Buendia Duque et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2019)
Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology
Rashmi R. Shah
DRUG SAFETY (2019)
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review
Xuanzong Li et al.
TARGETED ONCOLOGY (2018)
Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy
Guoqing Qian et al.
CANCER LETTERS (2018)
Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer
Azusa Tanimoto et al.
CLINICAL CANCER RESEARCH (2017)
Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo
Weiwei Yu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation
Puyu Shi et al.
CLINICAL CANCER RESEARCH (2017)
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going
A. Russo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition
Katrin Liffers et al.
TARGETED ONCOLOGY (2016)
SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin
Seong Joon Park et al.
TUMOR BIOLOGY (2016)
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment
Puyu Shi et al.
CANCER LETTERS (2016)
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Yixuan Li et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells
Gabriele Greve et al.
BMC CANCER (2015)
Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors
Michael Juchum et al.
DRUG RESISTANCE UPDATES (2015)
Overcoming Resistance to Targeted Therapy for Lung Cancer
Ramaswamy Govindan
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance
Alfredo Tartarone et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2015)
The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer
Tae-Gul Lee et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins
J. Remon et al.
CANCER TREATMENT REVIEWS (2014)
EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition
Takayuki Nakagawa et al.
CANCER RESEARCH (2013)
The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells
M-C Chen et al.
CELL DEATH & DISEASE (2013)
HDAC Inhibitor Vorinostat Enhances the Antitumor Effect of Gefitinib in Squamous Cell Carcinoma of Head and Neck by Modulating ErbB Receptor Expression and Reverting EMT
Francesca Bruzzese et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2011)
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy
Xuerong Wang et al.
CANCER BIOLOGY & THERAPY (2008)
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines
SE Witta et al.
CANCER RESEARCH (2006)
Extracellular signal-regulated kinases 1/2 are serum-stimulated BimEL kinases that bind to the BH3-only protein BimEL causing its phosphorylation and turnover
R Ley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function
F Luciano et al.
ONCOGENE (2003)
Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim
R Ley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
分享论文
